Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren versus irbesartan on inflammatory and cardiovascular risk biomarkers in hypertension with metabolic syndrome
2005-001176-12Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertension (HTN) and cardiometabolic risk (CMR) comparing Aliskiren arm with Irbesartan arm (2 arms). Started Dec 2005; status: completed.
02
Drugs
aliskirenirbesartan
03
Conditions
hypertension (HTN)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2005-001176-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001176-12.